MA38463A1 - Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines - Google Patents

Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines

Info

Publication number
MA38463A1
MA38463A1 MA38463A MA38463A MA38463A1 MA 38463 A1 MA38463 A1 MA 38463A1 MA 38463 A MA38463 A MA 38463A MA 38463 A MA38463 A MA 38463A MA 38463 A1 MA38463 A1 MA 38463A1
Authority
MA
Morocco
Prior art keywords
diseases
receptor antagonists
releasing hormone
gonadotropin releasing
spiroindoline derivatives
Prior art date
Application number
MA38463A
Other languages
English (en)
Other versions
MA38463B1 (fr
Inventor
Olaf Panknin
Stefan BÄURLE
Sven Ring
Katrin Nowak-Reppel
Reinhard Nubbemeyer
Gernot Langer
Andrea Wagenfeld
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48047908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38463(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38463A1 publication Critical patent/MA38463A1/fr
Publication of MA38463B1 publication Critical patent/MA38463B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des dérivés de la spiroindoline, des procédés pour leur préparation et des compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de maladies, et leur utilisation pour la fabrication de médicaments pour le traitement de maladies, notamment des maladies liées aux hormones sexuelles à la fois chez l'homme et la femme, en particulier celles choisies dans le groupe constitué par: l'endométriose, le fibromyome (léiomyomes), le syndrome des ovaires polykystiques, la ménorragie, la dysménorrhée, l'hirsutisme, la puberté précoce, les néoplasies gonadiques dues aux stéroïdes telles que les cancers de la prostate, du sein et des ovaires, les adénomes hypophysaires gonadotropes, l'apnée du sommeil, le syndrome du côlon irritable, le syndrome prémenstruel, l'hypertrophie prostatique bénigne, la contraception, l'infertilité et la thérapie reproductive assistée telle que la fécondation in vitro. La présente invention concerne en particulier des dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone de libération des gonadotrophines (gnrh).
MA38463A 2013-04-09 2014-04-08 Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines MA38463B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13162986 2013-04-09
PCT/EP2014/057079 WO2014166958A1 (fr) 2013-04-09 2014-04-08 Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines

Publications (2)

Publication Number Publication Date
MA38463A1 true MA38463A1 (fr) 2018-05-31
MA38463B1 MA38463B1 (fr) 2018-11-30

Family

ID=48047908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38463A MA38463B1 (fr) 2013-04-09 2014-04-08 Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines

Country Status (28)

Country Link
US (1) US20160052936A1 (fr)
EP (1) EP2984092A1 (fr)
JP (1) JP2016519104A (fr)
KR (1) KR20150139917A (fr)
CN (1) CN105308053A (fr)
AP (1) AP2015008822A0 (fr)
AR (1) AR095785A1 (fr)
AU (1) AU2014253232A1 (fr)
BR (1) BR112015025700A2 (fr)
CA (1) CA2908869A1 (fr)
CL (1) CL2015003013A1 (fr)
CR (1) CR20150530A (fr)
CU (1) CU20150141A7 (fr)
DO (1) DOP2015000259A (fr)
EA (1) EA201501000A1 (fr)
HK (1) HK1216101A1 (fr)
IL (1) IL241067A0 (fr)
MA (1) MA38463B1 (fr)
MX (1) MX2015014267A (fr)
NI (1) NI201500149A (fr)
PE (1) PE20160007A1 (fr)
PH (1) PH12015502318A1 (fr)
SG (1) SG11201506962TA (fr)
TN (1) TN2015000453A1 (fr)
TW (1) TW201518304A (fr)
UY (1) UY35526A (fr)
WO (1) WO2014166958A1 (fr)
ZA (1) ZA201508209B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
AP2014007738A0 (en) * 2012-01-16 2014-07-31 Bayer Ip Gmbh Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists

Also Published As

Publication number Publication date
IL241067A0 (en) 2015-11-30
UY35526A (es) 2014-11-28
AR095785A1 (es) 2015-11-11
JP2016519104A (ja) 2016-06-30
AP2015008822A0 (en) 2015-10-31
PH12015502318A1 (en) 2016-02-15
TW201518304A (zh) 2015-05-16
DOP2015000259A (es) 2015-11-15
EA201501000A1 (ru) 2016-04-29
CL2015003013A1 (es) 2016-04-08
WO2014166958A1 (fr) 2014-10-16
MA38463B1 (fr) 2018-11-30
CU20150141A7 (es) 2016-03-31
CA2908869A1 (fr) 2014-10-16
HK1216101A1 (zh) 2016-10-14
EP2984092A1 (fr) 2016-02-17
ZA201508209B (en) 2018-05-30
MX2015014267A (es) 2016-03-01
AU2014253232A1 (en) 2015-11-05
KR20150139917A (ko) 2015-12-14
PE20160007A1 (es) 2016-02-14
BR112015025700A2 (pt) 2017-07-18
CR20150530A (es) 2016-01-29
SG11201506962TA (en) 2015-10-29
US20160052936A1 (en) 2016-02-25
CN105308053A (zh) 2016-02-03
NI201500149A (es) 2015-11-30
TN2015000453A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
MA35867B1 (fr) Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)
Griesinger et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction
ES2245694T3 (es) Derivados de 11beta-pentil- y 11beta-hexil-estra-1,3,5(10)-trienos sustituidos en la posicion 8beta.
HRP20191049T1 (hr) (11beta, 17beta)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuorometil)estra-4,9-dien-3-on za uporabu za liječenje bolesti
JPH04506797A (ja) 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
JP2005532350A (ja) 新しいエトノゲストレルエステル
BR112014021331A8 (pt) Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses
EA202090461A1 (ru) Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза
WO2004017961A3 (fr) Composes chimiques
WO2007084211A3 (fr) Utilisation de ligands du gpr54 pour le traitement de troubles de la reproduction, de troubles proliferatifs et pour la contraception
MA38463B1 (fr) Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines
MX2022010439A (es) Antagonistas covalentes selectivos del receptor de androgenos (sarcas) y metodos de uso de los mismos.
BR9911564A (pt) Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto
CN104231025B (zh) 一种雌酚酮原料药杂质及其制备方法和作为标准品的用途
MA38465A1 (fr) Forme posologique de l'antagoniste du récepteur de la progestérone
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
CN116096371A8 (zh) 含有饱和含氧杂环基的嘧啶二酮类化合物及其用途
EP3464314A1 (fr) Dérivés d'oestrone substitués en 15b en tant qu'inhibiteurs sélectifs de 17b-hydroxystéroïdes déshydrogénases, leur procédé de préparation et leur utilisation
Avery et al. Synthesis and testing of 17aβ-hydroxy-7α-methyl-d-homoestra-4, 16-dien-3-one: a highly potent orally active androgen
CN1898258B (zh) 具有混合的雄激素和结合孕激素特性的类固醇
JP2006517947A (ja) 抗腫瘍活性２−置換１８ａ−ホモエストラ−１，３，５（１０）−トリエン−３−イルスルファメート
TN2011000022A1 (en) Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a - ring